Benitec Biopharma (ASX: BLT)

Benitec Biopharma (ASX: BLT) is a biotechnology company developing innovative therapeutics based on its patented gene-silencing technology called ddRNAi. www.benitec.com

Benitec Biopharma ASX BLT licensing deal Axovant Sciences oculopharyngeal muscular dystrophy drug

Benitec Biopharma secures multimillion-dollar licensing deal with Axovant Sciences

Biopharmaceutical company Benitec Biopharma (ASX: BLT) has decided to licence exclusive global rights to its proprietary oculopharyngeal muscular dystrophy...
Benitec Biopharma ASX BLT Russia oncology study Phase 2

Benitec Biopharma receives Russian regulatory approval for oncology study

Biopharmaceutical company Benitec Biopharma (ASX: BLT) is well on its way to generating clinical trial results for...
Benitec Biopharma ASX BLT FDA orphan drug oculopharyngeal muscular dystrophy

Benitec’s BB-301 muscular dystrophy drug granted FDA orphan status

Benitec Biopharma (ASX: BLT) has received orphan drug designation from the FDA for its BB-301 which has...
Benitec Biopharma BLT ASX US patent hepatitis B treatment

Benitec Biopharma secures US patent for hepatitis B treatment

Biotechnology company Benitec Biopharma (ASX: BLT) has secured a US patent for its hepatitis B treatment, which,...
Small Caps ASX Australian stock market
Small Caps is Australia's #1 site for news & information on ASX listed small cap companies.

Small Caps and affiliated companies accept no responsibility for any claim, loss or damage as a result of information provided or its accuracy. The information provided on this site is general in nature, not financial product advice, see a financial expert before making any investment decision. Your personal objectives, financial situation or needs have not been taken into consideration. There may be a conflict of interest present with commercial arrangements with companies and/or stock held. Small Caps or an associate may receive a commission for funds raised.
Copyright 2020 Small Caps. All rights reserved.